Approach to patients with elevated low-density lipoprotein cholesterol levels

Area of Science:

• Cardiology and Lipidology
• Preventive Medicine
• Clinical Practice Guidelines

Background:

• Elevated low-density lipoprotein cholesterol (LDL-C) is a primary risk factor for atherosclerotic cardiovascular disease (ASCVD).
• Identifying contributing factors to high LDL-C, including lifestyle, comorbidities, medications, and genetics, is crucial for effective management.
• Existing clinical guidelines for LDL-C reduction show some discordance in recommendations.

Purpose of the Study:

• To present key principles for guiding clinical decisions on initiating and intensifying LDL-C lowering therapy.
• To synthesize evidence supporting the benefits of early and more substantial LDL-C reductions.
• To aid clinicians in optimizing treatment strategies for patients with elevated LDL-C and varying ASCVD risk.

Main Methods:

• Review of current scientific literature and clinical guidelines concerning LDL-C management.
• Analysis of evidence linking LDL-C levels, treatment timing, and magnitude of reduction to ASCVD risk.
• Synthesis of principles to inform clinical decision-making in diverse patient populations.

Main Results:

• Evidence strongly supports that earlier initiation of LDL-C lowering therapy leads to better outcomes.
• Greater reductions in LDL-C levels correlate with more significant decreases in ASCVD risk.
• The benefits of LDL-C lowering treatment are amplified in individuals with higher baseline LDL-C levels and elevated ASCVD risk.

Conclusions:

• Implementing evidence-based principles can enhance the effectiveness of LDL-C management strategies.
• Personalized treatment decisions should prioritize early and aggressive LDL-C reduction based on individual risk profiles.
• These principles aim to improve patient outcomes by optimizing the approach to lowering LDL-C and mitigating ASCVD risk.